We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: metformin
MedXY News
EnglishTag

metformin

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice
newsadolescentsbipolar disorder

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice

By MedXY|Nov 17, 2025

A large, pragmatic randomized trial found that adjunctive metformin produced a modest but statistically significant reduction in BMI Z-score at 6 and 24 months among overweight and obese youth with bipolar spectrum disorders treated with se

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings
Cardiologycardiac surgery
metformin

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings

By MedXY|Nov 13, 2025

A retrospective MIMIC‑IV cohort presented at AHA 2025 found perioperative metformin exposure in T2DM patients undergoing cardiac surgery associated with markedly lower 30‑, 90‑ and 360‑day mortality. Results are compelling but observational

Metformin Does Not Improve Walking Distance in Peripheral Artery Disease: Results from the PERMET Randomized Trial
CardiologymetforminPeripheral Artery Disease

Metformin Does Not Improve Walking Distance in Peripheral Artery Disease: Results from the PERMET Randomized Trial

By MedXY|Nov 8, 2025

The PERMET randomized, double-blind trial found that 6 months of metformin did not improve 6-minute walk distance or other functional endpoints in people with lower extremity peripheral artery disease (PAD) without diabetes.

Metformin in Knee Osteoarthritis: Evaluating Its Role in Pain Relief and Disease Modification
Clinical Updatesknee osteoarthritismetformin

Metformin in Knee Osteoarthritis: Evaluating Its Role in Pain Relief and Disease Modification

By MedXY|Nov 1, 2025

Emerging evidence supports metformin’s modest pain-relieving effects and potential disease-modifying properties in knee osteoarthritis patients with overweight or obesity, warranting further investigation through larger trials.

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection
Diabetes & EndocrinologymetforminParkinson's disease

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection

By MedXY|Nov 1, 2025

A 20‑year TriNetX analysis of 913,428 T2DM patients found SGLT2 inhibitor use associated with a 28% lower Parkinson’s disease risk versus metformin (aHR 0.72), suggesting possible superior neuroprotection and prompting need for prospective

Sustained Impact of Lifestyle and Metformin Interventions on Type 2 Diabetes Prevention: Insights from 21 Years of the US DPP Trial
Diabetes & Endocrinologylifestyle interventionmetformin

Sustained Impact of Lifestyle and Metformin Interventions on Type 2 Diabetes Prevention: Insights from 21 Years of the US DPP Trial

By MedXY|Oct 29, 2025

Over 21 years, intensive lifestyle changes and metformin significantly reduced type 2 diabetes incidence in at-risk adults, with variable effects based on individual baseline risk factors, highlighting opportunities for precision prevention

Metformin and Age-Related Macular Degeneration: Current Evidence on Development and Progression
Ophthalmologyage-related macular degenerationcohort study

Metformin and Age-Related Macular Degeneration: Current Evidence on Development and Progression

By MedXY|Oct 21, 2025

This review synthesizes current evidence from large cohorts, meta-analyses, and randomized trials evaluating metformin’s association with AMD development and progression, highlighting a nuanced but inconclusive protective potential re

Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial
Clinical Updatesclinical trialmetformin

Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial

By MedXY|Oct 8, 2025

This phase III trial showed that adding lobeglitazone to metformin and sitagliptin significantly improves glycaemic control and insulin sensitivity with favorable safety over 52 weeks in Korean patients with type 2 diabetes inadequately con

Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet
Clinical UpdatesGLP-1gut microbiota

Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet

By MedXY|Oct 8, 2025

A fermentable carbohydrate-enriched diet combined with metformin improves postprandial glycaemia, enhances GLP-1 secretion, and positively alters gut microbiota in prediabetic individuals, offering a personalized nutrition-pharmacology stra

Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial
Diabetes & Endocrinologycurcuminhormonal therapy

Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial

By MedXY|Oct 8, 2025

A 12-week randomized trial demonstrates that combining metformin and nanocurcumin significantly improves lipid metabolism, glucose regulation, hormonal balance, and body metrics in women with PCOS, surpassing effects seen with either agent

Metformin with or without Mediterranean Diet Significantly Reduces Diabetes Risk in Metabolic Syndrome: Insights from the MeMeMe Trial
Diabetes & EndocrinologyMediterranean dietmetabolic syndrome

Metformin with or without Mediterranean Diet Significantly Reduces Diabetes Risk in Metabolic Syndrome: Insights from the MeMeMe Trial

By MedXY|Oct 8, 2025

The MeMeMe randomized trial shows that metformin 1,700 mg/day effectively prevents type 2 diabetes in metabolic syndrome patients, independent of Mediterranean diet adherence, with implications for age-related disease prevention.

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial
Clinical Updatesclinical trialcyclophosphamide

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial

By MedXY|Oct 8, 2025

The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-d

Metformin in Gynecologic Cancers: A Comprehensive Review of Evidence in Cervical, Ovarian, and Endometrial Cancer
Clinical Updatescervical cancerEndometrial Cancer

Metformin in Gynecologic Cancers: A Comprehensive Review of Evidence in Cervical, Ovarian, and Endometrial Cancer

By MedXY|Oct 8, 2025

This review synthesizes recent evidence on metformin’s therapeutic and prognostic roles in cervical, ovarian, and endometrial cancers, highlighting randomized trials, meta-analyses, and clinical outcomes with a focus on progression-fr

Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial
Clinical Updatescervical cancerchemoradiotherapy

Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial

By MedXY|Oct 8, 2025

This phase II study shows that adding metformin to standard chemoradiotherapy in locally advanced cervical cancer is safe, well tolerated, and feasible, with no significant increase in severe adverse events and successful biomarker-based tu

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial
OB/GYN & Women's Healthchemotherapyclinical trial

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

By MedXY|Oct 8, 2025

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm,

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide
Clinical Updatesmetforminobesity

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

By MedXY|Oct 7, 2025

Combination therapy with metformin and semaglutide improves weight loss, metabolic parameters, menstrual function, and natural pregnancy rates in overweight/obese women with PCOS compared to metformin alone.

Phase Ib Trial of Metformin Combined with Nivolumab in Refractory Solid Tumors: Safety, Dosage, and Preliminary Efficacy
newsmetforminNivolumab

Phase Ib Trial of Metformin Combined with Nivolumab in Refractory Solid Tumors: Safety, Dosage, and Preliminary Efficacy

By MedXY|Oct 7, 2025

A phase Ib study evaluated the safety, optimal dosing, pharmacokinetics, and preliminary efficacy of metformin with nivolumab in refractory solid tumors, showing good tolerability and promising responses in a subset of patients.

Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study
Clinical Updatesclinical trialmetformin

Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study

By MedXY|Oct 7, 2025

A phase II trial assessing oral metformin for low-grade non-muscle-invasive bladder cancer (NMIBC) found minimal antitumor activity and no significant mechanistic changes, challenging metformin’s role as an intravesical therapeutic agent in

Metformin: The Surprising Anti-Aging Ally Rewinding the Biological Clock
Family Medicine & Nutritionaginganti-aging

Metformin: The Surprising Anti-Aging Ally Rewinding the Biological Clock

By MedXY|Oct 7, 2025

Recent research reveals metformin’s potential to reverse biological aging by up to 20 years, igniting hope for anti-aging therapies and raising questions about its wider use.

Metformin and COVID-19 Symptom Resolution: Evidence from the ACTIV-6 Randomized Clinical Trial
Clinical UpdatesCOVID-19metformin

Metformin and COVID-19 Symptom Resolution: Evidence from the ACTIV-6 Randomized Clinical Trial

By MedXY|Oct 7, 2025

This review synthesizes recent evidence from the ACTIV-6 trial showing metformin does not significantly reduce symptom duration in low-risk adults with COVID-19, addressing safety, clinical outcomes, and translational insights.

Prev
2 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities